DK2205635T3 - Antigenbindende proteiner der er i stand til at binde thymisk stromalt lymfopoietin - Google Patents
Antigenbindende proteiner der er i stand til at binde thymisk stromalt lymfopoietin Download PDFInfo
- Publication number
- DK2205635T3 DK2205635T3 DK08830362.3T DK08830362T DK2205635T3 DK 2205635 T3 DK2205635 T3 DK 2205635T3 DK 08830362 T DK08830362 T DK 08830362T DK 2205635 T3 DK2205635 T3 DK 2205635T3
- Authority
- DK
- Denmark
- Prior art keywords
- tslp
- sequence
- ser
- antibody
- gly
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Claims (17)
1
1. Et anti-TSLP-humant antistof omfattende: a. et let kæde-variabelt domæne omfattende: i. et let kæde CDRl-sekvens omfattende aminosyresekvensen af SEQ ID 5 NO: 13; ii. en let kæde CDR2-sekvens omfattende aminosyresekvensen af SEQ ID NO:60; og iii. en let kæde CDR3-sekvens omfattende aminosyresekvensen af SEQ ID NO: 105; og 10 b. et tung kæde-variabelt domæne omfattende: i. en tung kæde CDRl-sekvens omfattende aminosyresekvensen af SEQ ID NO: 145; ii. en tung kæde CDR2-sekvens omfattende aminosyresekvensen af SEQ ID NO: 173, og 15 iii. en tung kæde CDR3-sekvens omfattende aminosyresekvensen af SEQ ID NO:212.
2. Anti-TSLP-humant antistof ifølge krav i, omfattende: a. en let kæde variabel domænesekvens valgt fra gruppen bestående af: 20 i. aminosyrer med en sekvens mindst 80% identisk med SEQ ID NO:363; ii. en sekvens af aminosyrer der er kodet af en polynukleotidsekvens der er mindst 80% identisk med SEQ ID NO:362; iii. en sekvens af aminosyrer der er kodet af en polynukleotidsekvens der hybridiserer under moderat stringente betingelser til komplementet af et 25 polynukleotid bestående af SEQ ID NO:362; 2 and b. en tung kæde-variabel domænesekvens valgt fra gruppen bestående af: i. en sekvens af aminosyrer der er mindst 80% identisk med SEQ ID NO:361; 5 ii. en sekvens af aminosyrer der er kodet af en polynukleotidsekvens der er mindst 80% identisk med SEQ ID NO:360; iii. en sekvens af aminosyrer der er kodet af en polynukleotidsekvens der hybridiserer under moderat stringente betingelser til komplementet af et polynukleotid bestående af SEQ ID NO:360. 10
3. Anti-TSLP-humant antistof ifølge krav 1, omfattende: et let kæde-variabelt domæne omfattende sekvensen af SEQ ID NO: 363 og et tung kæde-variabelt domæne omfattende sekvensen af SEQ ID NO: 361.
4. Anti-TSLP-humant antistof ifølge et hvilket som helst af kravene 1-2, hvor a. det anti-TSLP-humane antistof binder til TSLP med i det væsentlige det samme Kd som referenceantistoffet, og/eller b. hvor det anti-TSLP-humane antistof inhiberer TSLP-aktivitet i henhold til primærcelle-OPG-assayet med den samme IC50 som referenceantistoffet, 20 hvor referenceantistoffet er et antistof omfattende et let kæde-variabelt domæne omfattende aminosyresekvensen af SEQ ID NO:363 og et tung kæde-variabelt domæne omfattende aminosyresekvensen af SEQ ID NO:361.
5. Farmaceutisk sammensætning omfattende anti-TSLP-humant antistof ifølge et 25 hvilket som helst af kravene 1-4. 3
6. Nukleinsyre omfattende en polynukleotidsekvens der koder for det let kædevariable domæne og det tung kæde-variable domæne af anti-TSLP-humant antistof ifølge et hvilket som helst af kravene 1-4.
7. Rekombinant ekspressionsvektor omfattende nukleinsyren ifølge krav 6.
8. Værtscelle omfattende a) ekspressionsvektor omfattende et polynukleotid der koder for det let kæde-variable domæne og det tung kæde-variable domæne af det anti-TSLP-humant antistof ifølge et hvilket som helst af kravene 1-4; eller b) ekspressionsvektor omfattende et polynukleotid der koder for det let kæde-variable domæne af anti-TSLP-humant antistof ifølge et hvilket som helst af kravene 1-4 og en ekspressionsvektor omfattende et polynukleotid der koder for det tung kæde-variable domæne af det anti-TSLP-humane antistof ifølge et hvilket som helst af kravene 1-4.
9. Hybridom der er i stand til at producere anti-TSLP-humant antistof ifølge et hvilket som helst af kravene 1-4.
10. Fremgangsmåde til fremstilling af et anti-TSLP-humant antistof ifølge et hvilket som helst af kravene 1-4, omfattende inkubering af værtscellen ifølge krav 8 under betingelser der tillader det at udtrykke antistoffet.
11. Sammensætning ifølge krav 5 til anvendelse i behandling af a. en TSLP-beslægtet inflammatorisk tilstand hos et individ med behov for en sådan behandling; eller b. en TSLP-beslægtet fibrotisk lidelse hos et individ med behov for en sådan behandling.
12. Sammensætningen til anvendelse ifølge krav 11, hvor den inflammatoriske tilstand er valgt fra gruppen bestående af allergisk astma, allergisk rhinosinusitis, 4 allergisk konjunktivitis, og atopisk dermatitis.
13. Sammensætningen til anvendelse ifølge krav 11, hvor den fibrotiske lidelse er valgt fra gruppen bestående af scleroderma, interstitial lungesygdom, idiopatisk pulmonær fibrose, fibrose opstået fra kronisk hepatitis B eller C, stråle-induceret fibrose, og fibrose opstået fra sårheling.
14. Anti-TSLP-humant antistof ifølge krav 1, hvor det anti-TSLP-humane antistof er et monoklonalt antistof.
15. Anti-TSLP-humant antistof ifølge krav 1, hvor det anti-TSLP humane antistof omfatter a) en let kæde omfattende et let kæde-variabelt domæne omfattende aminosyresekvensen redegjort for i SEQ ID NO:363 og et lambda let kæde konstant domæne omfattende aminosyresekvensen redegjort for i SEQ ID NO:369; og b) en tung kæde omfattende et tung kæde-variabelt domæne omfattende aminosyresekvensen redegjort for i SEQ ID NO:361 og et IgG2 tung konstant domæne omfattende aminosyresekvensen redegjort for i SEQ ID NO:365.
16. Fremgangsmåde ifølge krav 10, hvor værtscellen er en CHO-celle.
17. Anti-TSLP-humant antistof opnåeligt ved fremgangsmåden ifølge krav 16.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97117807P | 2007-09-10 | 2007-09-10 | |
US9167608P | 2008-08-25 | 2008-08-25 | |
PCT/US2008/010510 WO2009035577A1 (en) | 2007-09-10 | 2008-09-09 | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2205635T3 true DK2205635T3 (da) | 2016-07-18 |
Family
ID=40242598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK08830362.3T DK2205635T3 (da) | 2007-09-10 | 2008-09-09 | Antigenbindende proteiner der er i stand til at binde thymisk stromalt lymfopoietin |
Country Status (36)
Country | Link |
---|---|
US (5) | US7982016B2 (da) |
EP (3) | EP2205635B1 (da) |
JP (7) | JP5956716B2 (da) |
KR (2) | KR20140141666A (da) |
CN (2) | CN101809035B (da) |
AR (1) | AR068508A1 (da) |
AU (1) | AU2008300028B2 (da) |
CA (1) | CA2698382C (da) |
CL (2) | CL2008002668A1 (da) |
CR (2) | CR11319A (da) |
CY (1) | CY1117702T1 (da) |
DK (1) | DK2205635T3 (da) |
EA (2) | EA201590631A1 (da) |
ES (1) | ES2581229T3 (da) |
FR (1) | FR22C1059I2 (da) |
HK (1) | HK1145843A1 (da) |
HR (1) | HRP20160638T1 (da) |
HU (2) | HUE028361T2 (da) |
IL (3) | IL204069A (da) |
JO (1) | JO3351B1 (da) |
LT (1) | LT2205635T (da) |
MX (1) | MX2010002590A (da) |
MY (1) | MY150242A (da) |
NL (1) | NL301207I2 (da) |
NO (1) | NO2022055I1 (da) |
NZ (1) | NZ583933A (da) |
PE (2) | PE20110668A1 (da) |
PH (1) | PH12017501025A1 (da) |
PL (1) | PL2205635T3 (da) |
PT (1) | PT2205635T (da) |
RS (1) | RS54950B1 (da) |
SG (2) | SG10201506251YA (da) |
SI (1) | SI2205635T1 (da) |
TW (2) | TW201412774A (da) |
WO (1) | WO2009035577A1 (da) |
ZA (1) | ZA201001895B (da) |
Families Citing this family (141)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0603683D0 (en) * | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
EP2628752A1 (en) | 2006-12-14 | 2013-08-21 | Merck Sharp & Dohme Corp. | Engineered anti-TSLP antibody |
AU2009206306B2 (en) | 2008-01-25 | 2013-06-06 | Amgen Inc. | Ferroportin antibodies and methods of use |
CN102782149B (zh) | 2009-11-04 | 2014-11-12 | 默沙东公司 | 经工程改造的抗-tslp抗体 |
EP2619226B1 (en) * | 2010-09-22 | 2018-09-12 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
WO2013067051A1 (en) * | 2011-11-03 | 2013-05-10 | Merck Sharp & Dohme Corp. | Biomarkers for tslp treatment |
SI3431492T1 (sl) * | 2012-04-27 | 2021-07-30 | Novo Nordisk A/S | Antigen-vezavni proteini liganda človeškega CD30 |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
US9708375B2 (en) | 2013-03-15 | 2017-07-18 | Amgen Inc. | Inhibitory polypeptides specific to WNT inhibitors |
CN104371019B (zh) * | 2013-08-13 | 2019-09-10 | 鸿运华宁(杭州)生物医药有限公司 | 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质 |
TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
EP3712166A1 (en) | 2013-09-05 | 2020-09-23 | Amgen Inc. | Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles |
WO2015118124A1 (en) * | 2014-02-06 | 2015-08-13 | Vib Vzw | Thymic stromal lymphopoietin receptor antagonist |
SG11201609219QA (en) | 2014-05-07 | 2016-12-29 | Amgen Inc | Autoinjector with shock reducing elements |
WO2015175861A1 (en) | 2014-05-16 | 2015-11-19 | Amgen Inc. | Assay for detecting th1 and th2 cell populations |
KR102506249B1 (ko) | 2014-06-03 | 2023-03-03 | 암겐 인코포레이티드 | 약물 전달 시스템 및 사용 방법 |
CA2957960C (en) | 2014-10-14 | 2023-08-22 | Amgen, Inc. | Drug injection device with visual and audible indicators |
CN114569716A (zh) | 2014-10-23 | 2022-06-03 | 美国安进公司 | 降低药物制剂的粘度 |
EP3233159B1 (en) | 2014-12-19 | 2020-03-04 | Amgen Inc. | Drug delivery device with live button or user interface field |
ES2748750T3 (es) | 2015-02-17 | 2020-03-17 | Amgen Inc | Dispositivo de administración de fármacos con sujeción asistida por vacío y/o realimentación |
ES2905870T3 (es) | 2015-02-27 | 2022-04-12 | Amgen Inc | Dispositivo de suministro de fármacos que tiene un mecanismo de protección de aguja con un umbral de resistencia ajustable al movimiento de la protección de aguja |
AR103891A1 (es) * | 2015-03-11 | 2017-06-14 | Glaxosmithkline Ip Dev Ltd | Proteínas de unión a tslp, ácido nucleico aislado que la codifica, vector y célula hospedadora que lo comprenden, método para producir dicha proteína, su uso para fabricar un medicamento, composición farmacéutica y kit que la comprenden |
IL293719B2 (en) * | 2015-05-21 | 2023-07-01 | Harpoon Therapeutics Inc | Trispecific binding proteins and methods of use |
WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
US10000561B2 (en) * | 2015-09-09 | 2018-06-19 | Novartis Ag | Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules |
RU2731644C2 (ru) | 2015-09-09 | 2020-09-07 | Новартис Аг | Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул |
US11351308B2 (en) | 2015-12-09 | 2022-06-07 | Amgen Inc. | Auto-injector with signaling cap |
US11154661B2 (en) | 2016-01-06 | 2021-10-26 | Amgen Inc. | Auto-injector with signaling electronics |
CN108884169B (zh) | 2016-01-22 | 2022-03-22 | 默沙东公司 | 抗凝血因子xi抗体 |
GB201615588D0 (en) * | 2016-09-14 | 2016-10-26 | Glaxosmithkline Ip Dev Ltd | TSLP Binding Proteins |
EP3721922B1 (en) | 2016-03-15 | 2022-05-04 | Amgen Inc. | Reducing probability of glass breakage in drug delivery devices |
WO2017174556A1 (en) | 2016-04-05 | 2017-10-12 | Vib Vzw | Novel tslp inhibitors |
WO2017189089A1 (en) | 2016-04-29 | 2017-11-02 | Amgen Inc. | Drug delivery device with messaging label |
WO2017192287A1 (en) | 2016-05-02 | 2017-11-09 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
AU2017263558B2 (en) | 2016-05-13 | 2022-12-22 | Amgen Inc. | Vial sleeve assembly |
US11238150B2 (en) | 2016-05-16 | 2022-02-01 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
US11541176B2 (en) | 2016-06-03 | 2023-01-03 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
AU2017286432B2 (en) | 2016-06-14 | 2020-09-24 | Adimab, Llc | Anti-coagulation factor XI antibodies |
WO2018004842A1 (en) | 2016-07-01 | 2018-01-04 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
RU2721582C1 (ru) * | 2016-08-05 | 2020-05-20 | И-Байолоджикс Инк. | Антитела против лиганда-1 запрограммированной смерти (PD-L1) и их применение |
US20190328965A1 (en) | 2016-08-17 | 2019-10-31 | Amgen Inc. | Drug delivery device with placement detection |
US20200261643A1 (en) | 2016-10-25 | 2020-08-20 | Amgen Inc. | On-body injector |
TWI784988B (zh) | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
AU2018210301A1 (en) | 2017-01-17 | 2019-08-01 | Amgen Inc. | Injection devices and related methods of use and assembly |
CN109476755B (zh) * | 2017-01-24 | 2020-12-04 | 天境生物科技(上海)有限公司 | Cd73抗体及其用途 |
JP7064501B2 (ja) | 2017-02-17 | 2022-05-10 | アムジエン・インコーポレーテツド | 無菌流体流路を備える薬物送達デバイスおよび関連する組立方法 |
AU2018221351B2 (en) | 2017-02-17 | 2023-02-23 | Amgen Inc. | Insertion mechanism for drug delivery device |
CA3050927A1 (en) | 2017-03-06 | 2018-09-13 | Brian Stonecipher | Drug delivery device with activation prevention feature |
IL268478B2 (en) | 2017-03-07 | 2023-10-01 | Amgen Inc | Inserting a needle using super pressure |
JP2020509837A (ja) | 2017-03-09 | 2020-04-02 | アムジエン・インコーポレーテツド | 薬剤送達装置のための挿入機構 |
AU2018235928B2 (en) | 2017-03-14 | 2023-09-21 | Amgen Inc. | Control of total afucosylated glycoforms of antibodies produced in cell culture |
CN110446512B (zh) | 2017-03-28 | 2022-03-18 | 美国安进公司 | 柱塞杆和注射器组件系统以及方法 |
JOP20190243A1 (ar) * | 2017-04-12 | 2019-10-13 | Medimmune Llc | علاج الربو بجسم مضاد لـ tslp |
MA48464A (fr) | 2017-04-28 | 2020-03-04 | Amgen Inc | Dipeptides n-acétylés et non acétylés contenant de l'arginine destinés à réduire la viscosité de compositions visqueuses de polypeptides thérapeutiques |
EP3634546A1 (en) | 2017-06-08 | 2020-04-15 | Amgen Inc. | Torque driven drug delivery device |
US11590294B2 (en) | 2017-06-08 | 2023-02-28 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
MX2019015472A (es) | 2017-06-22 | 2020-02-19 | Amgen Inc | Reduccion del impacto/choque de la activacion del mecanismo. |
WO2018237225A1 (en) | 2017-06-23 | 2018-12-27 | Amgen Inc. | ELECTRONIC DRUG DELIVERY DEVICE COMPRISING A CAP ACTIVATED BY A SWITCH ASSEMBLY |
CN109206514B (zh) * | 2017-07-03 | 2019-10-08 | 拜西欧斯(北京)生物技术有限公司 | Tslp单克隆抗体及其制备方法和应用 |
EP3651832B1 (en) | 2017-07-14 | 2023-12-13 | Amgen Inc. | Needle insertion-retraction system having dual torsion spring system |
MA49626A (fr) | 2017-07-21 | 2020-05-27 | Amgen Inc | Élément d'étanchéité perméable aux gaz pour récipient à médicament et procédés d'assemblage |
WO2019022950A1 (en) | 2017-07-25 | 2019-01-31 | Amgen Inc. | DRUG DELIVERY DEVICE WITH CONTAINER ACCESS SYSTEM AND ASSEMBLY METHOD THEREOF |
WO2019022951A1 (en) | 2017-07-25 | 2019-01-31 | Amgen Inc. | DRUG DELIVERY DEVICE WITH GEAR MODULE AND ASSEMBLY METHOD THEREOF |
KR102560646B1 (ko) | 2017-08-01 | 2023-07-27 | 암젠 인크 | 질량 분광분석법으로의 분석을 위한 폴리펩티드 샘플의 실시간 제조를 위한 시스템 및 방법 |
MX2020001171A (es) | 2017-08-01 | 2020-03-12 | Amgen Inc | Sistemas y metodos para realizar un ensayo de glicanos en tiempo real de una muestra. |
EP3664863A2 (en) | 2017-08-09 | 2020-06-17 | Amgen Inc. | Hydraulic-pneumatic pressurized chamber drug delivery system |
AU2018318435A1 (en) | 2017-08-16 | 2020-04-02 | Medimmune, Llc | Compositions and methods for treatment of atopic dermatitis and treatment selection |
MA49897A (fr) | 2017-08-18 | 2020-06-24 | Amgen Inc | Injecteur sur-corps avec patch adhésif stérile |
US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
WO2019070472A1 (en) | 2017-10-04 | 2019-04-11 | Amgen Inc. | FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE |
CN111132711B (zh) | 2017-10-06 | 2022-07-01 | 安进公司 | 带有联锁组件的药物递送装置及相关组装方法 |
EP3694578A1 (en) | 2017-10-09 | 2020-08-19 | Amgen Inc. | Drug delivery device with drive assembly and related method of assembly |
WO2019090079A1 (en) | 2017-11-03 | 2019-05-09 | Amgen Inc. | System and approaches for sterilizing a drug delivery device |
WO2019090303A1 (en) | 2017-11-06 | 2019-05-09 | Amgen Inc. | Fill-finish assemblies and related methods |
WO2019089178A1 (en) | 2017-11-06 | 2019-05-09 | Amgen Inc. | Drug delivery device with placement and flow sensing |
CA3079665A1 (en) | 2017-11-10 | 2019-05-16 | Amgen Inc. | Plungers for drug delivery devices |
WO2019099324A1 (en) | 2017-11-16 | 2019-05-23 | Amgen Inc. | Door latch mechanism for drug delivery device |
AU2019234739A1 (en) | 2018-03-13 | 2020-09-03 | Amgen Inc. | Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis |
EP3765857A1 (en) | 2018-03-13 | 2021-01-20 | Amgen Inc. | Sequential digestion of polypeptides for mass spectrometric analysis |
MA52186A (fr) | 2018-03-26 | 2021-02-17 | Amgen Inc | Glycoformes afucosylées totales d'anticorps produits en culture cellulaire |
US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
US20210228815A1 (en) | 2018-07-24 | 2021-07-29 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
CA3103682A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Delivery devices for administering drugs |
EP3826701A1 (en) | 2018-07-24 | 2021-06-02 | Amgen Inc. | Delivery devices for administering drugs |
WO2020023220A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation |
EP3829692A1 (en) | 2018-07-31 | 2021-06-09 | Amgen Inc. | Fluid path assembly for a drug delivery device |
MA53724A (fr) | 2018-09-24 | 2021-12-29 | Amgen Inc | Systèmes et procédés de dosage interventionnel |
JP7425049B2 (ja) | 2018-09-25 | 2024-01-30 | ハープーン セラピューティクス,インク. | Dll3結合タンパク質および使用方法 |
AU2019350660A1 (en) | 2018-09-28 | 2021-03-18 | Amgen Inc. | Muscle wire escapement activation assembly for a drug delivery device |
AR116679A1 (es) | 2018-10-02 | 2021-06-02 | Amgen Inc | Sistemas de inyección para la administración de fármacos con transmisión de fuerza interna |
EP3860686A1 (en) | 2018-10-05 | 2021-08-11 | Amgen Inc. | Drug delivery device having dose indicator |
CA3109988A1 (en) | 2018-10-15 | 2020-04-23 | Amgen Inc. | Platform assembly process for drug delivery device |
SG11202103800RA (en) | 2018-10-15 | 2021-05-28 | Amgen Inc | Drug delivery device having damping mechanism |
EP3873566A1 (en) | 2018-11-01 | 2021-09-08 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
MA54057A (fr) | 2018-11-01 | 2022-02-09 | Amgen Inc | Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament |
WO2020092056A1 (en) | 2018-11-01 | 2020-05-07 | Amgen Inc. | Drug delivery devices with partial needle retraction |
CA3126018A1 (en) | 2018-12-14 | 2020-06-18 | Amgen Inc. | System suitability method for use with protein concentration determination by slope |
WO2020142693A1 (en) * | 2019-01-04 | 2020-07-09 | Empirico Inc. | Treatment of thymic stromal lymphopoietin (tslp) related diseases by inhibition of long-form tslp transcripts |
WO2020168156A1 (en) | 2019-02-14 | 2020-08-20 | Amgen Inc. | Systems and methods for preparing a sample and performing a real-time assay of the sample |
WO2020172293A1 (en) | 2019-02-20 | 2020-08-27 | Amgen Inc. | Methods of determining protein stability |
US20230035363A1 (en) | 2019-03-04 | 2023-02-02 | Amgen Inc. | In vivo reversibility of high molecular weight species |
CA3133459A1 (en) | 2019-03-27 | 2020-10-01 | Amgen Inc. | Methods of fingerprinting therapeutic proteins via a two-dimensional (2d) nuclear magnetic resonance technique at natural abundance for formulated biopharmaceutical products |
US20220160972A1 (en) | 2019-04-24 | 2022-05-26 | Amgen Inc. | Syringe sterilization verification assemblies and methods |
MX2021014804A (es) | 2019-06-04 | 2022-01-18 | Jiangsu Hengrui Medicine Co | Anticuerpo capaz de unirse a la linfopoyetina estromal timica y el uso del mismo. |
JP2022535042A (ja) | 2019-06-05 | 2022-08-04 | アムジエン・インコーポレーテツド | 治療用タンパク質の属性を特定する方法 |
CA3148261A1 (en) | 2019-08-23 | 2021-03-04 | Amgen Inc. | Drug delivery device with configurable needle shield engagement components and related methods |
WO2021062372A1 (en) | 2019-09-26 | 2021-04-01 | Amgen Inc. | Methods of producing antibody compositions |
AR120309A1 (es) * | 2019-10-28 | 2022-02-09 | Medimmune Ltd | Formulaciones de polvo seco de anticuerpos que se unen a la linfopoyetina del estroma tímico (tslp) y métodos de uso de las mismas |
CN112876564B (zh) * | 2019-11-29 | 2022-07-15 | 康诺亚生物医药科技(成都)有限公司 | 一种tslp相关病症治疗剂的开发和应用 |
JP2023505408A (ja) * | 2019-12-13 | 2023-02-09 | シチュアン ケルン-バイオテック バイオファーマシューティカル カンパニー リミテッド | 抗tslp抗体及びその使用 |
TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法 |
CN111171150B (zh) * | 2020-02-05 | 2020-12-08 | 北京智仁美博生物科技有限公司 | 抗人tslp抗体及其用途 |
JP2023513312A (ja) | 2020-02-13 | 2023-03-30 | アムジェン インコーポレイテッド | ヒト抗tslp抗体の製剤及び炎症性疾患を治療する方法 |
WO2021163588A1 (en) | 2020-02-13 | 2021-08-19 | Amgen Inc. | Treatment of atopic dermatitis with anti-tslp antibody |
MX2022010120A (es) | 2020-02-18 | 2022-09-05 | Amgen Inc | Formulaciones de anticuerpos anti-tslp humanos y metodos de uso de los mismos. |
CN111662379B (zh) * | 2020-05-09 | 2021-03-02 | 江苏省疾病预防控制中心(江苏省公共卫生研究院) | 抗新型冠状病毒的抗体、制备方法和应用 |
KR20230024904A (ko) * | 2020-05-20 | 2023-02-21 | 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 | Sars-cov-2에 대한 강력한 중화 항체, 그의 생성 및 용도 |
EP4162257A1 (en) | 2020-06-04 | 2023-04-12 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
US20230349912A1 (en) | 2020-09-18 | 2023-11-02 | Amgen Inc. | Methods of processing a sample for peptide mapping analysis |
EP4229080A1 (en) | 2020-10-15 | 2023-08-23 | Amgen Inc. | Relative unpaired glycans in antibody production methods |
EP4240747A1 (en) | 2020-11-05 | 2023-09-13 | Amgen Inc. | Materials and methods for protein processing |
CN114437212B (zh) * | 2020-11-06 | 2023-03-14 | 上海麦济生物技术有限公司 | 抗人胸腺基质淋巴细胞生成素抗体及其制备方法和应用 |
WO2022117079A1 (zh) * | 2020-12-03 | 2022-06-09 | 江苏恒瑞医药股份有限公司 | 结合胸腺基质淋巴细胞生成素的抗体及其应用 |
CN113501878B (zh) | 2021-02-03 | 2022-12-02 | 北京智仁美博生物科技有限公司 | 针对人tslp的多种抗体及其用途 |
JP2024504441A (ja) * | 2021-02-04 | 2024-01-31 | スタイドソン・(ベイジン)・バイオファーマシューティカルズ・カンパニー・リミテッド | 胸腺間質性リンパ球新生因子を特異的に認識する抗体およびその使用 |
EP4326766A1 (en) | 2021-04-23 | 2024-02-28 | Amgen Inc. | Anti-tslp antibody compositions and uses thereof |
AR125404A1 (es) | 2021-04-23 | 2023-07-12 | Amgen Inc | Anticuerpos anti-tslp modificados |
WO2022246055A1 (en) | 2021-05-21 | 2022-11-24 | Amgen Inc. | Method of optimizing a filling recipe for a drug container |
CA3217029A1 (en) * | 2021-05-30 | 2022-12-08 | Biolojic Design Ltd. | Engineered dual binding antibodies and uses thereof |
EP4352094A1 (en) | 2021-06-07 | 2024-04-17 | Amgen Inc. | Using fucosidase to control afucosylation level of glycosylated proteins |
CN113069543B (zh) * | 2021-06-07 | 2021-08-06 | 迈威(上海)生物科技股份有限公司 | 包含抗胸腺基质淋巴细胞生成素的单克隆抗体的液体组合物 |
CN113683694B (zh) | 2021-09-03 | 2022-05-13 | 江苏荃信生物医药股份有限公司 | 一种抗人tslp单克隆抗体及其应用 |
WO2023059607A1 (en) | 2021-10-05 | 2023-04-13 | Amgen Inc. | Fc-gamma receptor ii binding and glycan content |
WO2023070948A1 (zh) * | 2021-11-01 | 2023-05-04 | 江苏荃信生物医药股份有限公司 | 包含抗人胸腺基质淋巴细胞生成素(tslp)单克隆抗体的浓缩溶液的制备方法及液体制剂 |
WO2023086793A1 (en) | 2021-11-09 | 2023-05-19 | Amgen Inc. | Production of therapeutic proteins |
CN117209604B (zh) * | 2021-12-02 | 2024-03-22 | 北京东方百泰生物科技股份有限公司 | 一种抗tslp的单克隆抗体、其抗原结合片段及其应用 |
CN114369654B (zh) * | 2021-12-21 | 2023-11-07 | 广州市妇女儿童医疗中心 | 川崎病的生物标志物及其应用 |
TW202337898A (zh) * | 2021-12-24 | 2023-10-01 | 新加坡商創響私人有限公司 | 新穎的抗-tslp抗體 |
WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
US20240034780A1 (en) * | 2022-07-22 | 2024-02-01 | Flagship Pioneering Innovations Vi, Llc | Antigen Binding Molecules Targeting Thymic Stromal Lymphopoietin (TSLP) |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
USRE32011E (en) | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
JPS58117537A (ja) | 1982-01-06 | 1983-07-13 | Toray Ind Inc | 感光性樹脂組成物 |
EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5011912A (en) | 1986-12-19 | 1991-04-30 | Immunex Corporation | Hybridoma and monoclonal antibody for use in an immunoaffinity purification system |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
AU629958B2 (en) | 1989-06-15 | 1992-10-15 | Immunex Corporation | Interleukin-7 receptors |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
DK0639079T3 (da) | 1992-04-30 | 2000-06-13 | Amgen Inc | Fremgangsmåder til behandling af interleukin-1- og tumornekrosefaktor-medierede sygdomme |
AU678787B2 (en) | 1992-10-23 | 1997-06-12 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
WO1995000103A2 (en) | 1993-06-15 | 1995-01-05 | Il-Yang Pharm. Co., Ltd. | Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof |
US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
US6613544B1 (en) | 1995-12-22 | 2003-09-02 | Amgen Inc. | Osteoprotegerin |
DK1500329T3 (da) | 1996-12-03 | 2012-07-09 | Amgen Fremont Inc | Humane antistoffer, der specifikt binder TNF-alfa |
GB9702944D0 (en) | 1997-02-13 | 1997-04-02 | Univ Manchester | Reducing fibrosis |
US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
US6673901B2 (en) | 1997-06-12 | 2004-01-06 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
US6844170B1 (en) * | 1998-03-19 | 2005-01-18 | Human Genome Sciences, Inc. | Cytokine receptor common gamma chain like |
EP1982990A1 (en) | 1998-03-19 | 2008-10-22 | Human Genome Sciences, Inc. | Cytokine receptor common gamma chain like |
US6982320B2 (en) | 1998-03-19 | 2006-01-03 | Human Genome Sciences, Inc. | Cytokine receptor common gamma chain like |
US6210924B1 (en) | 1998-08-11 | 2001-04-03 | Amgen Inc. | Overexpressing cyclin D 1 in a eukaryotic cell line |
CA2343979C (en) | 1998-09-21 | 2011-11-15 | Schering Corporation | Human interleukin-b50, therapeutic uses |
US20030099947A1 (en) | 1998-09-21 | 2003-05-29 | Bazan J. Fernando | Mammalian cytokines; related reagents and methods |
EP1129190B2 (en) | 1998-11-13 | 2017-01-11 | Immunex Corporation | Human tslp dna and polypeptides |
EP1140976A4 (en) | 1998-12-30 | 2003-05-21 | Millennium Pharm Inc | SECRETED PROTEINS AND THEIR USES |
US20010021380A1 (en) | 1999-04-19 | 2001-09-13 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
GB9928787D0 (en) | 1999-12-03 | 2000-02-02 | Medical Res Council | Direct screening method |
EP2329842A3 (en) | 2000-05-12 | 2011-07-27 | Immunex Corporation | Interleukin-1 inhibitors in the treatment of diseases |
AU2001271624A1 (en) | 2000-06-28 | 2002-01-08 | Whitehead Institute For Biomedical Research | Thymic stromal lymphopoietin receptor molecules and uses thereof |
WO2002000724A2 (en) | 2000-06-28 | 2002-01-03 | Amgen, Inc. | Thymic stromal lymphopoietin receptor molecules and uses thereof |
GB0025144D0 (en) | 2000-10-13 | 2000-11-29 | Medical Res Council | Concatenated nucleic acid sequences |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
CN1234728C (zh) * | 2001-05-16 | 2006-01-04 | 上海睿星基因技术有限公司 | 新的人淋巴因子、其编码序列及用途 |
WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
DK1417231T3 (da) | 2001-07-23 | 2013-07-22 | Immunex Corp | Modificeret human thymisk stromal lymphopoietin |
EP2311869B2 (en) | 2002-02-01 | 2020-06-17 | Merck Sharp & Dohme Corp. | Use of mammalian cytokine-related reagents |
HRP20020453A2 (en) | 2002-05-23 | 2003-12-31 | Pliva D D | 1,3-diaza-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediate for preparation thereof |
NZ593428A (en) | 2002-09-06 | 2013-01-25 | Amgen Inc | Therapeutic human anti-il-1r1 monoclonal antibody |
US20040202995A1 (en) | 2003-04-09 | 2004-10-14 | Domantis | Nucleic acids, proteins, and screening methods |
PT1651247E (pt) | 2003-07-18 | 2008-12-15 | Schering Corp | Tratamento e diagnóstico de neoplasmas utilizando linfopoietina de estroma tímico |
JP5105874B2 (ja) | 2003-07-18 | 2012-12-26 | アムジエン・インコーポレーテツド | 肝細胞増殖因子に対する特異的結合因子 |
PT1718677E (pt) | 2003-12-19 | 2012-07-18 | Genentech Inc | Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos |
US20050249712A1 (en) * | 2004-03-23 | 2005-11-10 | The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services | Methods for use of TSLP and agonists and antagonists thereof |
CA2577631A1 (en) | 2004-08-20 | 2006-03-02 | Amgen Inc. | Methods and compositions for treating allergic inflammation |
WO2006055638A2 (en) * | 2004-11-17 | 2006-05-26 | Abgenix, Inc. | Fully human monoclonal antibodies to il-13 |
ES2776657T3 (es) | 2005-06-14 | 2020-07-31 | Amgen Inc | Formulaciones de proteínas autotamponantes |
US8097705B2 (en) | 2006-01-13 | 2012-01-17 | Irm Llc | Methods and compositions for treating allergic diseases |
GB0603683D0 (en) * | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
EP2628752A1 (en) | 2006-12-14 | 2013-08-21 | Merck Sharp & Dohme Corp. | Engineered anti-TSLP antibody |
CA2691157A1 (en) | 2007-06-20 | 2008-12-24 | Irm Llc | Methods and compositions for treating allergic diseases |
JP5782185B2 (ja) | 2012-06-01 | 2015-09-24 | 日本電信電話株式会社 | パケット転送処理方法およびパケット転送処理装置 |
US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
-
2008
- 2008-09-08 US US12/231,944 patent/US7982016B2/en active Active
- 2008-09-09 EP EP08830362.3A patent/EP2205635B1/en active Active
- 2008-09-09 EA EA201590631A patent/EA201590631A1/ru unknown
- 2008-09-09 ES ES08830362.3T patent/ES2581229T3/es active Active
- 2008-09-09 HU HUE08830362A patent/HUE028361T2/en unknown
- 2008-09-09 CN CN200880106436.1A patent/CN101809035B/zh active Active
- 2008-09-09 NZ NZ583933A patent/NZ583933A/en unknown
- 2008-09-09 PT PT88303623T patent/PT2205635T/pt unknown
- 2008-09-09 EA EA201000471A patent/EA022796B1/ru not_active IP Right Cessation
- 2008-09-09 SI SI200831642A patent/SI2205635T1/sl unknown
- 2008-09-09 TW TW102140859A patent/TW201412774A/zh unknown
- 2008-09-09 CN CN201410253054.9A patent/CN104231081B/zh active Active
- 2008-09-09 DK DK08830362.3T patent/DK2205635T3/da active
- 2008-09-09 MY MYPI2010000985A patent/MY150242A/en unknown
- 2008-09-09 KR KR20147029417A patent/KR20140141666A/ko not_active Application Discontinuation
- 2008-09-09 CA CA2698382A patent/CA2698382C/en active Active
- 2008-09-09 RS RS20160490A patent/RS54950B1/sr unknown
- 2008-09-09 PL PL08830362.3T patent/PL2205635T3/pl unknown
- 2008-09-09 EP EP13178927.3A patent/EP2703414A1/en not_active Ceased
- 2008-09-09 SG SG10201506251YA patent/SG10201506251YA/en unknown
- 2008-09-09 JO JOP/2008/0401A patent/JO3351B1/ar active
- 2008-09-09 WO PCT/US2008/010510 patent/WO2009035577A1/en active Application Filing
- 2008-09-09 TW TW097134513A patent/TWI449709B/zh active
- 2008-09-09 LT LTEP08830362.3T patent/LT2205635T/lt unknown
- 2008-09-09 MX MX2010002590A patent/MX2010002590A/es active IP Right Grant
- 2008-09-09 JP JP2010524055A patent/JP5956716B2/ja active Active
- 2008-09-09 CL CL2008002668A patent/CL2008002668A1/es unknown
- 2008-09-09 AU AU2008300028A patent/AU2008300028B2/en active Active
- 2008-09-09 SG SG2012009817A patent/SG178781A1/en unknown
- 2008-09-09 EP EP19152495.8A patent/EP3524622A1/en active Pending
- 2008-09-09 KR KR1020107007193A patent/KR101597371B1/ko active IP Right Grant
- 2008-09-10 AR ARP080103923A patent/AR068508A1/es active IP Right Grant
- 2008-09-17 PE PE2008001578A patent/PE20110668A1/es not_active Application Discontinuation
- 2008-09-17 PE PE2013001432A patent/PE20140232A1/es active IP Right Grant
-
2010
- 2010-02-21 IL IL204069A patent/IL204069A/en active IP Right Grant
- 2010-03-17 CR CR11319A patent/CR11319A/es unknown
- 2010-03-17 ZA ZA2010/01895A patent/ZA201001895B/en unknown
- 2010-12-29 HK HK10112210.7A patent/HK1145843A1/zh unknown
-
2011
- 2011-07-18 US US13/185,021 patent/US8163284B2/en active Active
-
2012
- 2012-04-03 US US13/438,739 patent/US9284372B2/en active Active
- 2012-11-21 CL CL2012003245A patent/CL2012003245A1/es unknown
-
2014
- 2014-12-01 JP JP2014243277A patent/JP2015091820A/ja active Pending
-
2015
- 2015-02-24 CR CR20150095A patent/CR20150095A/es unknown
-
2016
- 2016-02-03 US US15/014,828 patent/US10287348B2/en active Active
- 2016-06-09 HR HRP20160638TT patent/HRP20160638T1/hr unknown
- 2016-06-29 CY CY20161100597T patent/CY1117702T1/el unknown
-
2017
- 2017-01-06 JP JP2017000937A patent/JP2017110011A/ja active Pending
- 2017-03-02 IL IL250900A patent/IL250900A0/en unknown
- 2017-06-02 PH PH12017501025A patent/PH12017501025A1/en unknown
-
2018
- 2018-11-09 JP JP2018211180A patent/JP2019038843A/ja active Pending
-
2019
- 2019-04-04 IL IL265854A patent/IL265854A/en unknown
- 2019-05-08 US US16/406,811 patent/US20200071393A1/en active Pending
- 2019-12-18 JP JP2019227914A patent/JP2020058365A/ja active Pending
-
2021
- 2021-08-16 JP JP2021132141A patent/JP2021191758A/ja active Pending
-
2022
- 2022-12-09 NO NO2022055C patent/NO2022055I1/no unknown
- 2022-12-12 HU HUS2200051C patent/HUS2200051I1/hu unknown
- 2022-12-12 NL NL301207C patent/NL301207I2/nl unknown
- 2022-12-12 FR FR22C1059C patent/FR22C1059I2/fr active Active
-
2023
- 2023-02-02 JP JP2023014362A patent/JP2023065375A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2205635T3 (da) | Antigenbindende proteiner der er i stand til at binde thymisk stromalt lymfopoietin | |
CA2662613C (en) | Compositions and methods relating to glucagon receptor antibodies | |
JP5775615B2 (ja) | アルファ−4−ベータ−7ヘテロ二量体特異的アンタゴニスト抗体 | |
CN101835489B (zh) | Il-18受体抗原结合蛋白 | |
AU2014277673A1 (en) | Antigen Binding Proteins Capable of Binding Thymic Stromal Lymphopoietin |